Search clinical trials for: schizophrenia

Total 3958 results

Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Comparison of the Pharmacokinetics and Safety of Long-acting Injectable Risperidone When Administered to Gluteal or Deltoid Intramuscular Injection Sites in Stable Schizophrenia Patients.

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Compare the Effectiveness and Safety of Flexibly Varied Doses of Paliperidone Palmitate and Risperidone in Treating Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Potential Effects of Trimethoprim on the Pharmacokinetics of ER OROS Paliperidone

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Trial Evaluating the Efficacy and Safety of 2 Fixed Doses of Paliperidone Extended-Release (ER) Tablets in the Treatment of Adult Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Safety Study With Paliperidone ER Extended-Release (ER) Tablets in Geriatric Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Long Term Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia

Schizophrenia
Cyrenaic Pharmaceuticals

Completed

Study of CYR-101 in Patients With Schizophrenia

Schizophrenia

France
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Effectiveness and Safety of 3 Doses of Paliperidone Palmitate in Treating Subjects With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Effectiveness and Safety of Topiramate in the Treatment of Patients With Bipolar Disorder

Mood Disorders | Bipolar Disorders | Affective Disorders, Psychotic
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A 52 Week Open Label Extension Trial Following the Recurrence Prevention Study R076477-SCH-301 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia.

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release Formulations

Schizophrenia | Schizoaffective Disorder
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Efficacy and Safety of a Long Acting Anti-Psychotic Versus Placebo in Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Study Evaluating and Comparing Single Dose and Multiple Dose Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese and Caucasian Adults.

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Investigate Risperidone for the Treatment of Schizophrenia in Adolescents

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder

Psychotic Disorders | Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Effect of Food on the Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese Volunteers

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Pharmacokinetics of Paliperidone in Volunteers With Normal or Impaired Liver Function

Schizophrenia | Hepatic Impairment
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Effectiveness and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia

Psychotic Disorders | Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder

Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorders
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Safety and Tolerability Study of Paliperidone Palmitate Injected in the Shoulder or the Buttock Muscle in Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Bioequivalence Study of 15 mg ER OROS Paliperidone

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

The Efficacy and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of QT and QTc Intervals in Patients Administered Immediate Release Paliperidone

Schizophrenia | Schizoaffective Disorder
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Effectiveness and Safety of Paliperidone Extended-release (ER) Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia.

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A 52-week, Open-label Extension Study Following a 6-week, Double-blind, Placebo- and Active- Controlled Study (R076477-SCH-303) to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release Formulations

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release Formulations

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Plasma Concentrations, Metabolism and Excretion of 14C-paliperidone After a Single Oral Dose

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A 52 Week Open-label Extension Trial Following the Double-blind Efficacy and Safety Study R076477-SCH-305.

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Trial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Paliperidone Enantiomer Disposition With Different Formulations and the Bioavailability of Immediate- and Extended-release Paliperidone

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Dose-proportionality Study of Five Tablet Strengths of ER OROS Paliperidone

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Safety and Efficacy of an Anti-Psychotic in Patients With Schizophrenia

Schizophrenia
Far Eastern Memorial Hospital
National Taiwan University Hospital

Unknown

Expanding Rapid Ascertainment Networks of Schizophrenia Families in Taiwan

Schizophrenia

Taiwan
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Effects of Paroxetine on the Pharmacokinetics of Paliperidone ER

Schizophrenia
Janssen-Cilag, S.A.

Completed

ADH.E.R.E.: Therapeutic ADHerence and Treatment Strategies: A Mental Health Registry

Depression | Schizophrenia | Bipolar Disorder | Personality Disorder
Janssen-Cilag, S.A.

Terminated

Study on the Safety and Effectiveness of Risperidone Treatment of Acute Psychotic Patients

Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorders
Xian-Janssen Pharmaceutical Ltd.

Completed

A Randomized, Active-controlled, Double-blind, Parallel-Goup Study of the Efficacy and Safety of Extended Release(ER) Paliperidone in the Treatment of Schizophrenia

Acute Schizophrenia

China
Janssen-Cilag, S.A.

Terminated

Study on the Safety of Risperidone on Obese or Overweight Patients With Schizophrenia

Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorder
Janssen-Cilag, S.A.

Completed

PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective Disorders

Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorder
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Injection Site Tolerability of Multiple Dose Treatment With Long-acting Injectable Risperidone Administered Via Deltoid Muscle in Chronic Schizophrenia Patients.

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I Disorder

Bipolar Disorder | Mania | Affective Psychosis, Bipolar
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-acting Risperidone by Injection

Psychotic Disorders | Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or Quetiapine

Schizophrenia | Schizoaffective Disorder

3

Subscribe